Staurus announces issuance of US patent for immunoglobulins and variants directed against pathogenic microbes
CALIFORNIA
– August 30, 2016 Staurus Pharma LLC, announced that the United
States Patent and Trademark Office has granted a key patent covering the
composition of novel Fc variant antibodies for the treatment for Staphylococcus aureus (S.aureus) infections. The immunoglobulins of the
claimed Fc variants prevent bacterial virulence factors from neutralizing the
effector function of anti-S. aureus therapeutic
antibodies. Such Fc modifications can be applied to any existing anti-S.aureus therapeutic monoclonal antibody to
improve efficacy.
This newly allowed patent covers
proprietary Immunoglobulin Fc modifications, which should significantly expand
anti-S.aureus therapeutic
opportunities beyond traditional antibiotics. Because mAbs do not bind to the
same bacterial targets as antibiotics, this new therapeutic approach could be
particularly useful in the treatment of antibiotic resistant
infections. They may also complement antibiotics in the management of
immunocompromised patients. In addition, mAbs have significantly longer
half-lives, providing compliance advantages (single dose) and less toxicity to
the normal body flora.
“At Staurus, we have dedicated ourselves
to understanding why host anti-S.aureus antibodies are not able to
effectively protect patients from life threatening complications following S.aureus infections. Circumventing microbial
immune evasion through engineering Fc variant antibodies that do not bind to S.aureus Fc Binding Proteins (FcBPs) is
central to this novel approach. Having an issued U.S. patent is a critical step
in the development of this important antibody-based therapeutic approach,” said
Nick Lydon, Co-founder of Staurus Pharma LLC. “The issued patent will protect
this novel Fc variant antibody technology and allow Staurus to work with a
number of collaborators to select the best anti-S.aureus antibody candidates for further
development.”
U.S. Patent No. 9,416,171 B2, entitled
“Immunoglobulins and variants directed against pathogenic microbes,” provides
commercial rights in the United States through March 2036.
Source: http://blog.ip.com/2016/08/staurus-announces-issuance-of-u-s-patent-for-immunoglobulins-and-variants-directed-against-pathogenic-microbes/